Ondine Biomedical Inc.
OBI.L · LSE
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Market Cap | £48 | £33 | £30 | £41 |
| - Cash | £10 | £1 | £3 | £4 |
| + Debt | £0 | £0 | £1 | £1 |
| Enterprise Value | £38 | £32 | £27 | £37 |
| Revenue | £1 | £1 | £1 | £0 |
| % Growth | -22.8% | 12.8% | 77.6% | – |
| Gross Profit | £0 | £0 | £0 | -£0 |
| % Margin | 44.5% | 29.9% | 22.7% | -10% |
| EBITDA | -£6 | -£4 | -£6 | -£8 |
| % Margin | -926.9% | -487.5% | -837.7% | -1,804.8% |
| Net Income | -£6 | -£8 | -£6 | -£8 |
| % Margin | -952.6% | -903.6% | -840.2% | -1,845.8% |
| EPS Diluted | -0.021 | -0.019 | -0.032 | -0.041 |
| % Growth | -12.3% | 41.9% | 21.3% | – |
| Operating Cash Flow | -£5 | -£7 | -£5 | -£8 |
| Capital Expenditures | £0 | -£0 | £0 | -£0 |
| Free Cash Flow | -£5 | -£7 | -£5 | -£8 |